The clinical challenges of homologous recombination proficiency in ovarian cancer: from intrinsic resistance to new treatment opportunities

Abstract

Ovarian cancer is the most lethal gynecologic cancer. Optimal cytoreductive surgery followed by platinum-based chemotherapy with or without bevacizumab is the conventional therapeutic strategy. Since 2016, the pharmacological treatment of epithelial ovarian cancer has significantly changed following the introduction of the poly (ADP-ribose) polymerase inhibitors (PARPi). BRCA1/2 mutations and homologous recombination deficiency (HRD) have been established as predictive biomarkers of the benefit from platinum-based chemotherapy and PARPi. While in the absence of HRD (the so-called homologous recombination proficiency, HRp), patients derive minimal benefit from PARPi, the use of the antiangiogenic agent bevacizumab in first line did not result in different efficacy according to the presence of homologous recombination repair (HRR) genes mutations. No clinical trials have currently compared PARPi and bevacizumab as maintenance therapy in the HRp population. Different strategies are under investigation to overcome primary and acquired resistance to PARPi and to increase the sensitivity of HRp tumors to these agents. These tumors are characterized by frequent amplifications of Cyclin E and MYC, resulting in high replication stress. Different agents targeting DNA replication stress, such as ATR, WEE1 and CHK1 inhibitors, are currently being explored in preclinical models and clinical trials and have shown promising preliminary signs of activity. In this review, we will summarize the available evidence on the activity of PARPi in HRp tumors and the ongoing research to develop new treatment options in this hard-to-treat population.

Keywords

PARP inhibitors / homologous recombination proficiency / ovarian cancer / PARP inhibitor resistance / replication stress

References

[1] National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer stat facts: ovarian cancer. Available from: https://seer.cancer.gov/statfacts/html/ovary.html. [Last accessed on 26 Jul 2023]

[2] Colombo N,du Bois A.ESMO-ESGO Ovarian Cancer Consensus Conference Working GroupESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†.Ann Oncol2019;30:672-705

[3] Henderson JT,Sawaya GF. Screening for ovarian cancer: an updated evidence review for the U.S. preventive services task force. 2018. Available from: https://www.ncbi.nlm.nih.gov/books/NBK493399/. [Last accessed on 26 Jul 2023]

[4] Hanker LC,Burchardi N.AGO and GINECO study groupThe impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy.Ann Oncol2012;23:2605-12

[5] Tewari KS,Enserro D.Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer.J Clin Oncol2019;37:2317-28 PMCID:PMC6879307

[6] Perren TJ,Pfisterer J.ICON7 InvestigatorsA phase 3 trial of bevacizumab in ovarian cancer.N Engl J Med2011;365:2484-96

[7] Tew WP,Ellis A.PARP inhibitors in the management of ovarian cancer: ASCO guideline.J Clin Oncol2020;38:3468-93 PMCID:PMC8942301

[8] Rouleau M,Hendzel MJ,Poirier GG.PARP inhibition: PARP1 and beyond.Nat Rev Cancer2010;10:293-301 PMCID:PMC2910902

[9] Bai P.Biology of poly(ADP-Ribose) polymerases: the factotums of cell maintenance.Mol Cell2015;58:947-58

[10] Zhang S,Li S.Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer.Gynecol Oncol2011;121:353-7

[11] Gudmundsdottir K.The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability.Oncogene2006;25:5864-74

[12] Iglehart JD.Synthetic lethality - a new direction in cancer-drug development.N Engl J Med2009;361:189-91

[13] Lord CJ.PARP inhibitors: synthetic lethality in the clinic.Science2017;355:1152-8 PMCID:PMC6175050

[14] Moore K,Scambia G.Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer.N Engl J Med2018;379:2495-505

[15] Ray-Coquard I,Pignata S.PAOLA-1 InvestigatorsOlaparib plus bevacizumab as first-line maintenance in ovarian cancer.N Engl J Med2019;381:2416-28

[16] González-Martín A,Vergote I.PRIMA/ENGOT-OV26/GOG-3012 InvestigatorsNiraparib in patients with newly diagnosed advanced ovarian cancer.N Engl J Med2019;381:2391-402

[17] Pujade-Lauraine E,Selle F.SOLO2/ENGOT-Ov21 investigatorsOlaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.Lancet Oncol2017;18:1274-84

[18] Banerjee S,Colombo N.Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol2021;22:1721-31

[19] Penson RT,Cibula D.Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1/2 mutation (SOLO3): a randomized phase III trial.J Clin Oncol2020;38:1164-74 PMCID:PMC7145583

[20] Mirza MR,Herrstedt J.ENGOT-OV16/NOVA InvestigatorsNiraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer.N Engl J Med2016;375:2154-64

[21] Moore KN,Geller MA.Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.Lancet Oncol2019;20:636-48

[22] Coleman RL,Lorusso D.ARIEL3 investigatorsRucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet2017;390:1949-61 PMCID:PMC5901715

[23] Swisher EM,Oza AM.Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.Lancet Oncol2017;18:75-87

[24] Lord CJ.The DNA damage response and cancer therapy.Nature2012;481:287-94

[25] Kanchi KL,Lu C.Integrated analysis of germline and somatic variants in ovarian cancer.Nat Commun2014;5:3156 PMCID:PMC4025965

[26] The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma.Nature2011;474:609-15 PMCID:PMC3163504

[27] Konstantinopoulos PA,Shapiro GI.Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer.Cancer Discov2015;5:1137-54 PMCID:PMC4631624

[28] Miller RE,Scott CL.ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.Ann Oncol2020;31:1606-22

[29] Vergote I,Ray-Coquard I.European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer.Ann Oncol2022;33:276-87

[30] Konstantinopoulos PA,Lacchetti C.Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline.J Clin Oncol2020;38:1222-45 PMCID:PMC8842911

[31] Moschetta M,Kaye SB.BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer.Ann Oncol2016;27:1449-55

[32] Hennessy BT,Carey MS.Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.J Clin Oncol2010;28:3570-6 PMCID:PMC2917312

[33] Swisher EM,Oza AM.Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2).Nat Commun2021;12:2487 PMCID:PMC8093258

[34] Pujade-Lauraine E,Barnicle A.Homologous recombination repair mutation gene panels (excluding BRCA) are not predictive of maintenance olaparib plus bevacizumab efficacy in the first-line PAOLA-1/ENGOT-ov25 trial.Gynecol Oncol2021;162:S26-7

[35] Musacchio L,Marchetti C.Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors.Int J Gynecol Cancer2023;33:922-8

[36] Lindor NM,Wang X.A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS).Hum Mutat2012;33:8-21 PMCID:PMC3242438

[37] Abkevich V,Hennessy BT.Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer.Br J Cancer2012;107:1776-82 PMCID:PMC3493866

[38] Birkbak NJ,Kim JY.Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents.Cancer Discov2012;2:366-75

[39] Popova T,Rieunier G.Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation.Cancer Res2012;72:5454-62

[40] Kondrashova O,Shield-Artin K.AOCS Study GroupSecondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma.Cancer Discov2017;7:984-98 PMCID:PMC5612362

[41] Lheureux S,Burnier JV.Somatic BRCA1/2 recovery as a resistance mechanism after exceptional response to poly (ADP-ribose) polymerase inhibition.J Clin Oncol2017;35:1240-9

[42] Tobalina L,Irving E,Forment JV.A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance.Ann Oncol2021;32:103-12

[43] Lovberix L,Busschaert P.Predictive value of the Leuven HRD test compared with Myriad myChoice PLUS on 468 ovarian cancer samples from the PAOLA-1/ENGOT-ov25 trial (LBA 6).Gynecol Oncol2022;166:S51-2

[44] Capoluongo ED,Arenare L.Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial.ESMO Open2022;7:100585 PMCID:PMC9512829

[45] Alexandrov LB,Haradhvala NJ.The repertoire of mutational signatures in human cancer.Nature2020;578:94-101 PMCID:PMC7054213

[46] Nik-Zainal S,Staaf J.Landscape of somatic mutations in 560 breast cancer whole-genome sequences.Nature2016;534:47-54

[47] Davies H,Morganella S.HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.Nat Med2017;23:517-25

[48] Hillman RT,Lu KH.Genomic rearrangement signatures and clinical outcomes in high-grade serous ovarian cancer.J Natl Cancer Inst2018;110:265-72 PMCID:PMC6054271

[49] Gulhan DC,Melloni GEM,Park PJ.Detecting the mutational signature of homologous recombination deficiency in clinical samples.Nat Genet2019;51:912-9

[50] Castroviejo-Bermejo M,Llop-Guevara A.A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.EMBO Mol Med2018;10:e9172 PMCID:PMC6284440

[51] Cruz C,Gutiérrez-Enríquez S.RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.Ann Oncol2018;29:1203-10 PMCID:PMC5961353

[52] Guffanti F,Anastasia A.Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts.Br J Cancer2022;126:120-8 PMCID:PMC8727677

[53] Blanc-Durand F,Genestie C.Evaluation of a RAD51 functional assay in advanced ovarian cancer, a GINECO/GINEGEPS study.J Clin Oncol2021;39:5513

[54] Ferron G,Ray-Coquard IL.The CHIVA study: a GINECO randomized double blind phase II trial of nintedanib versus placebo with the neo-adjuvant chemotherapy (NACT) strategy for patients (pts) with advanced unresectable ovarian cancer (OC). Report of the interval debulking surgery (IDS) safety outcome.Ann Oncol2016;27:VI297

[55] Michelena J,Teloni F,Imhof R.Analysis of PARP inhibitor toxicity by multidimensional fluorescence microscopy reveals mechanisms of sensitivity and resistance.Nat Commun2018;9:2678 PMCID:PMC6041334

[56] Fuh K,Blachut B.Homologous recombination deficiency real-time clinical assays, ready or not?.Gynecol Oncol2020;159:877-86

[57] Boyd J,Federici MG.Clinicopathologic features of BRCA-linked and sporadic ovarian cancer.JAMA2000;283:2260-5

[58] Gourley C,Roxburgh P.Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype.J Clin Oncol2010;28:2505-11

[59] Safra T,Nicoletto MO.BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin.Mol Cancer Ther2011;10:2000-7

[60] Banerjee S,Ashworth A.Making the best of PARP inhibitors in ovarian cancer.Nat Rev Clin Oncol2010;7:508-19

[61] Takaya H,Takamatsu S,Matsumura N.Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma.Sci Rep2020;10:2757 PMCID:PMC7026096

[62] Sims TT,Westin SN.Correlation of HRD status with clinical and survival outcomes in patients with advanced-stage ovarian cancer.J Clin Oncol2021;39:5568

[63] Stronach EA,Timms KM.Biomarker assessment of HR deficiency, tumor BRCA1/2 mutations, and CCNE1 copy number in ovarian cancer: associations with clinical outcome following platinum monotherapy.Mol Cancer Res2018;16:1103-11

[64] Patch AM,Etemadmoghadam D.Australian Ovarian Cancer Study GroupWhole-genome characterization of chemoresistant ovarian cancer.Nature2015;521:489-94

[65] Etemadmoghadam D,Au-Yeung G.Synthetic lethality between CCNE1 amplification and loss of BRCA1.Proc Natl Acad Sci U S A2013;110:19489-94 PMCID:PMC3845173

[66] Jones RM,Afzal I.Increased replication initiation and conflicts with transcription underlie cyclin E-induced replication stress.Oncogene2013;32:3744-53

[67] Vafa O,Kern S.c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability.Mol Cell2002;9:1031-44

[68] Nagao S,Leary A.176O final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC).Ann Oncol2022;33:S1503-4

[69] Monk BJ,Lim MC.A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45).J Clin Oncol2022;40:3952-64 PMCID:PMC9746782

[70] Coleman RL,Brady MF.Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer.N Engl J Med2019;381:2403-15 PMCID:PMC6941439

[71] GlaxoSmithKline: Dear health care provider letter, May 2022. Available from: https://www.zejulahcp.com/content/dam/cf-pharma/hcp-zejulahcp-v2/en_US/pdf/ZEJULA%20(niraparib)%20Dear%20HCP%20Letter.pdf. [Last accessed on 26 Jul 2023]

[72] Mirza MR,Birrer MJ.Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.Lancet Oncol2019;20:1409-19

[73] Aghajanian C,Goff BA.OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.J Clin Oncol2012;30:2039-45 PMCID:PMC3646321

[74] Oza AM,Pfisterer J.Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.Lancet Oncol2015;16:928-36 PMCID:PMC4648090

[75] Norquist BM,Harrell MI.Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218: an NRG oncology/gynecologic oncology group study.Clin Cancer Res2018;24:777-83 PMCID:PMC5815909

[76] Ribeiro ARG,de Brot L.Retrospective analysis of the role of cyclin E1 overexpression as a predictive marker for the efficacy of bevacizumab in platinum-sensitive recurrent ovarian cancer.Ecancermedicalscience2021;15:1262 PMCID:PMC8426016

[77] Hettle R,Lee CK.Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer.Ther Adv Med Oncol2021;13:17588359211049639 PMCID:PMC8488507

[78] Pignata S,Joly F.Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.Lancet Oncol2021;22:267-76

[79] Pilié PG,Mills GB.State-of-the-art strategies for targeting the DNA damage response in cancer.Nat Rev Clin Oncol2019;16:81-104 PMCID:PMC8327299

[80] Rehman FL,Ashworth A.The promise of combining inhibition of PI3K and PARP as cancer therapy.Cancer Discov2012;2:982-4

[81] Sun C,Yin J.Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers.Sci Transl Med2017;9:eaal5148 PMCID:PMC5919217

[82] Ha DH,Kim S.Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer.Sci Rep2020;10:9930 PMCID:PMC7303169

[83] Johnson N,Walton ZE.Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.Nat Med2011;17:875-82 PMCID:PMC3272302

[84] Wilson AJ,Barrack T.Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib.Gynecol Oncol2016;143:143-51 PMCID:PMC5031537

[85] Gupta VG,Petersen S.Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.Gynecol Oncol2021;162:163-72 PMCID:PMC8647995

[86] Andrikopoulou A,Koutsoukos K,Zagouri F.Clinical perspectives of BET inhibition in ovarian cancer.Cell Oncol2021;44:237-49

[87] Karakashev S,Yokoyama Y.BET bromodomain inhibition synergizes with PARP inhibitor in epithelial ovarian cancer.Cell Rep2017;21:3398-405 PMCID:PMC5745042

[88] Wilson AJ,Liu P,Khabele D.The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.Gynecol Oncol2018;149:575-84 PMCID:PMC5986599

[89] Konstantinopoulos PA,Birrer M.Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.Lancet Oncol2019;20:570-80 PMCID:PMC7025391

[90] Bindra RS,Meng A.Hypoxia-induced down-regulation of BRCA1 expression by E2Fs.Cancer Res2005;65:11597-604

[91] Kurnit KC,Hess K.Abstract CT020: phase I dose escalation of olaparib (PARP inhibitor) and selumetinib (MEK inhibitor) combination in solid tumors with Ras pathway alterations.Cancer Res2019;79:CT020

[92] Johnson SF,Greifenberg AK.CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-negative breast cancer.Cell Rep2016;17:2367-81 PMCID:PMC5176643

[93] Xia Q,Peng R,Shi Y.The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition.Int J Oncol2014;44:735-44

[94] Lee JM,Zimmer A.Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.Lancet Oncol2018;19:207-15 PMCID:PMC7366122

[95] Do KT,Kelland S.Phase 1 combination study of the CHK1 inhibitor prexasertib and the PARP inhibitor olaparib in high-grade serous ovarian cancer and other solid tumors.Clin Cancer Res2021;27:4710-6

[96] Fang Y,Sun C.Sequential therapy with PARP and WEE1 inhibitors minimizes toxicity while maintaining efficacy.Cancer Cell2019;35:851-867.e7 PMCID:PMC6642675

[97] Westin SN,Fellman BM.EFFORT: EFFicacy Of adavosertib in parp ResisTance: a randomized two-arm non-comparative phase II study of adavosertib with or without olaparib in women with PARP-resistant ovarian cancer.J Clin Oncol2021;39:5505

[98] Kim H,George E.Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models.Nat Commun2020;11:3726 PMCID:PMC7381609

[99] Wethington SL,Martin LP.Combination of PARP and ATR inhibitors (olaparib and ceralasertib) shows clinical activity in acquired PARP inhibitor-resistant recurrent ovarian cancer.J Clin Oncol2021;39:5516

[100] Dobbelstein M.Exploiting replicative stress to treat cancer.Nat Rev Drug Discov2015;14:405-23

[101] Chen XX,Zhu XJ.Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer.Oncotarget2015;6:14926-39 PMCID:PMC4558126

[102] Au-Yeung G,Azar WJ.Selective targeting of cyclin E1-amplified high-grade serous ovarian cancer by cyclin-dependent kinase 2 and AKT inhibition.Clin Cancer Res2017;23:1862-74 PMCID:PMC5364079

[103] Yi J,Tao Z.MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer.EBioMedicine2019;43:225-37 PMCID:PMC6557734

[104] Gallo D,Fourtounis J.CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition.Nature2022;604:749-56 PMCID:PMC9046089

[105] Konstantinopoulos PA,Wahner Hendrickson AE.Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial.Lancet Oncol2020;21:957-68 PMCID:PMC8023719

[106] Konstantinopoulos PA,Gulhan D.A replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer.Nat Commun2021;12:5574 PMCID:PMC8458434

[107] Lheureux S,Bruce JP.Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.Lancet2021;397:281-92

[108] Moore KN,Hamilton EP.Adavosertib with chemotherapy in patients with primary platinum-resistant ovarian, fallopian tube, or peritoneal cancer: an open-label, four-arm, phase II study.Clin Cancer Res2022;28:36-44

[109] Oza AM,Grischke EM.A biomarker-enriched, randomized phase II trial of adavosertib (AZD1775) plus paclitaxel and carboplatin for women with platinum-sensitive TP53-mutant ovarian cancer.Clin Cancer Res2020;26:4767-76

[110] Au-yeung G,Prall O.IGNITE: a phase II signal-seeking trial of adavosertib targeting recurrent high-grade, serous ovarian cancer with cyclin E1 overexpression with and without gene amplification.J Clin Oncol2022;40:5515

[111] Stover EH,Konstantinopoulos PA,Liu JF.Clinical assays for assessment of homologous recombination DNA repair deficiency.Gynecol Oncol2020;159:887-98